前列腺癌Gleason评分与最大限度雄激素阻断治疗的相关性

发布时间：2018-03-27 15:48

本文选题：前列腺癌　切入点：Gleason评分　出处：《中国老年学杂志》2017年21期

【摘要】：目的探讨不同前列腺癌(PCa)穿刺标本Gleason评分(GS)与最大限度雄激素阻断治疗(MAB)效果的相关性。方法 80例PCa患者,29例因自行中断治疗、随访失败及未按计划复查前列腺特异抗原水平(PSA)而被排除,入组51例,25例采用手术去势+抗雄药物治疗(双侧睾丸切除术联合非类固醇抗雄激素药物氟他胺),26例采用药物去势+抗雄药物治疗(戈舍瑞林联合非类固醇抗雄激素药物比卡鲁胺),入组病例均于治疗前、治疗后3、6个月进行血清PSA测定。结果两组治疗效果差异无统计学意义(P0.05)。根据GS进行分组,各组治疗前、治疗后3、6个月后的血清总PSA水平差异无统计学意义(P0.05)。结论手术去势+抗雄药组与药物去势+抗雄药物治疗疗效无明显差异。前列腺癌穿刺标本GS与MAB无显著相关性。
[Abstract]:Objective to investigate the correlation between Gleason score and maximum androgen blockade in different prostate cancer (PCA) puncture specimens. Methods Twenty nine patients with PCa were treated with spontaneous interruption of treatment. Failure of follow-up and failure to review the prostate specific antigen level (PSAs) as planned were excluded. Twenty-five patients were treated with ovariectomized androgenic drugs (bilateral orchiectomy combined with nonsteroidal androgen drug flutamide in 26 cases) (Goserelin combined with non-steroidal anti-androgen therapy). The hormone drug was better than Carous amines, and all the patients entered the group before treatment. Serum PSA was measured 3 and 6 months after treatment. Results there was no significant difference in treatment effect between the two groups (P 0.05). There was no significant difference in serum total PSA levels between 3 and 6 months after treatment. Conclusion there was no significant difference between castrated anti-androgenic drug group and castrated anti-androgenic drug group. There was no significant correlation between GS and MAB in prostate cancer samples.
【作者单位】：吉林大学第四医院(一汽总医院);吉林大学第一医院;济宁医学院附属医院;
【基金】：国家自然科学基金课题(81272471) 吉林省自然科学基金课题(201115066)
【分类号】：R737.25

【相似文献】